Timo Rath

Title: Timo Rath: Innovator in Fc Receptor Binding Peptides

Introduction

Timo Rath is a notable inventor based in Cambridge, MA (US). He has made significant contributions to the field of biochemistry, particularly in the development of peptides that interact with the neonatal Fc receptor (FcRn). With a total of 4 patents, his work has the potential to impact various medical treatments.

Latest Patents

Rath's latest patents focus on Fc receptor (FcRn) binding peptides and their uses. The inventions include isolated polypeptides that specifically block the interaction between FcRn and albumin. This blocking mechanism is crucial for treating diseases and conditions caused by elevated levels of albumin or modified albumin with pathogenic properties. The methods provided in these patents aim to decrease albumin levels effectively. Additionally, the inventions encompass isolated polypeptides capable of binding to a non-IgG and non-albumin competitive site on the FcRn alpha 3 domain. These polypeptides can be utilized for tracking FcRn without inhibiting the binding or function of IgG or albumin.

Career Highlights

Throughout his career, Timo Rath has worked with esteemed organizations such as Brigham and Women's Hospital, Inc. and Biogen MA Inc. His experience in these institutions has allowed him to collaborate with leading experts in the field, enhancing his research and innovation capabilities.

Collaborations

Some of Timo Rath's notable coworkers include Richard S. Blumberg and Kristi Baker. Their collaborative efforts have contributed to advancing research in the area of Fc receptor binding peptides.

Conclusion

Timo Rath's innovative work in the development of Fc receptor binding peptides showcases his commitment to advancing medical science. His patents hold promise for treating conditions related to albumin levels, marking him as a significant figure in the field of biochemistry.